---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027406"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:00:05.883670+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience reports Q3 FY2023 revenue of $63.7M (up 14% YoY); CFO to transition to new role

## Summary
- Revenue $63.7M, up 14% YoY from $56.1M; net loss $57.4M ($1.01/share) vs $60.5M prior year.
- CFO James Thorburn will transition to a new commercial/scaling role once successor is hired; search underway.
- Cash and investments $357.1M at June 30, 2023; shipped products to ~2,200 customers.
- Launched RNA sequencing portfolio; entered collaboration with Cancer Research Horizons.

## SEC filing metadata
- accession: 0001628280-23-027406
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/0001628280-23-027406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/twist-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027406
- JSON: https://secwatch.observer/filing/0001628280-23-027406.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027406.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported the third quarter of fiscal 2023 ended June 30, 2023 results: revenue $63.7 million.
  - Period: the third quarter of fiscal 2023 ended June 30, 2023
  - Revenue: $63.7 million
  - Result: reported results
  source text: Century Archive workflow by the end of calendar 2023. " FISCAL 2023 THIRD QUARTER FINANCIAL RESULTS • Orders: Total orders received for the third quarter of fiscal 2023 were $63.8 million compared to $59.7 million for the same period of fiscal 2022 . • Revenue: Total revenues for the third quarter of fiscal 2023 were $63.7 million compared to $56.1 million for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/0001628280-23-027406-index.htm
- Executive change
  James Thorburn changed role as Chief Financial Officer at Twist Bioscience Corp.
  - Action: transition to a new role
  - Role: Chief Financial Officer
  source text: On August 3, 2023, the Company and James Thorburn, the Company's Chief Financial Officer, mutually agreed that Mr. Thorburn will transition to a new role responsible for guiding the Company’s commercial scaling, operational leverage and DNA data storage business, once a new Chief Financial Officer is appointed.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828023027406/0001628280-23-027406-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.